Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank

Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced it has no accounts at the recently collapsed Silicon Valley Bank, providing reassurance to shareholders and the investment community. The company focuses on cancer treatment and prevention, with ongoing projects in ovarian and breast cancer immunotherapy. Anixa partners with renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its novel CAR-T and vaccine technologies. These initiatives aim to target specific cancer types, particularly the aggressive triple-negative breast cancer and ovarian cancer.

Positive

• Anixa has no exposure to the collapsed Silicon Valley Bank, alleviating investor concerns.
• Partnerships with esteemed institutions like Moffitt Cancer Center and Cleveland Clinic enhance its research credibility.
• Focus on innovative CAR-T and vaccine technologies could lead to significant advancements in cancer treatment.

Negative

• None.

SAN JOSE, Calif., March 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today reassured its shareholders and the investment community that it does not have any accounts at recently collapsed Silicon Valley Bank.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.  Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.  To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-reassures-shareholders-it-has-no-accounts-at-silicon-valley-bank-301769606.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa Biosciences announce on March 13, 2023?

Anixa announced it has no accounts at the collapsed Silicon Valley Bank, reassuring its shareholders.

What is Anixa Biosciences focused on?

Anixa focuses on the treatment and prevention of cancer, specifically through immunotherapy and vaccine development.

What partnerships does Anixa Biosciences have?

Anixa collaborates with Moffitt Cancer Center for ovarian cancer treatment and with Cleveland Clinic for breast cancer vaccine development.

What technologies is Anixa developing?

Anixa is developing CAR-T technology for ovarian cancer and vaccines for ovarian and triple-negative breast cancer.